Evidence map›Paper›PMID 41993615›Full record

ArticleTheranostics2026

Ganglioside enhances the immunogenicity of nanoparticles displaying short synthetic tumor neoepitopes and epitopes.

Shiqi Zhou, Yuan Luo, Maarten K Nijen Twilhaar, Wei-Chiao Huang, Amal Seffouh, Yiting Song, Yafei Su, Breandan Quinn, Yun Wu, Sriram Neelamegham and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shiqi ZhouDepartment of Biomedical Engineering. University at Buffalo, State University of New York, Buffalo, New York 14260, United States.
Yuan LuoDepartment of Biomedical Engineering. University at Buffalo, State University of New York, Buffalo, New York 14260, United States.
Maarten K Nijen TwilhaarDepartment of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Wei-Chiao HuangDepartment of Biomedical Engineering. University at Buffalo, State University of New York, Buffalo, New York 14260, United States.
Amal SeffouhMcGill University, Montreal, QC, Canada.
Yiting SongDepartment of Biomedical Engineering. University at Buffalo, State University of New York, Buffalo, New York 14260, United States.
Yafei SuDepartment of Biomedical Engineering. University at Buffalo, State University of New York, Buffalo, New York 14260, United States.
Breandan QuinnDepartment of Biomedical Engineering. University at Buffalo, State University of New York, Buffalo, New York 14260, United States.
Yun WuDepartment of Biomedical Engineering. University at Buffalo, State University of New York, Buffalo, New York 14260, United States.
Sriram NeelameghamDepartment of Chemical and Biological Engineering, University at Buffalo, State University of New York, 906 Furnas Hall, Buffalo, NY 14260, United States.
Joaquin OrtegaMcGill University, Montreal, QC, Canada.
Joke M M den HaanDepartment of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Jonathan F LovellDepartment of Biomedical Engineering. University at Buffalo, State University of New York, Buffalo, New York 14260, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Short major histocompatibility class I epitopes can be coupled to the surface of immunogenic liposomes to elicit antigen-specific CD8 Methods: Liposomes were formed with GM3 incorporated and were assessed for CD169 targeting and anti-tumor immunogenicity in murine models. Antigen-specific CD8 Results: GM3 was readily incorporated into immunogenic liposomes and did not interfere with the particle formation with a recently discovered murine renal carcinoma MHC-I neoepitope, Nes2LR. GM3 enhanced the CD169 targeting of liposomes. Immunization with liposomal particles that included GM3 improved antigen-specific CD8 Conclusion: GM3 ganglioside-containing liposomes that display short peptide epitopes and incorporate immunological adjuvants can be used to elicit potent anti-tumor responses in murine models. Further research is required to further assess the translational potential of this approach.

Indexed as

Antigens, NeoplasmCancer VaccinesEpitopesGangliosidesG(M3) GangliosideNanoparticlesAnimalsCD8-Positive T-LymphocytesFemaleLiposomesMiceMice, Inbred C57BLNanovaccinesProtein Subunit VaccinesAntigens, NeoplasmCancer VaccinesEpitopesGangliosidesG(M3) GangliosideLiposomesNanovaccinesProtein Subunit VaccinescancerCD8+ T cellgangliosideimmunotherapyliposomesshort peptidevaccine

Identifiers

PMID41993615
PMCPMC13080682

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.